IP Library Granted Patent US 11,173,175
Granted Patent B2
US 11,173,175 · App. 15/239,614 · Granted Nov 16, 2021

Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells

Inventor: Byeong-Chel Lee (Pittsburgh, PA)
Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
A61K31/7072A61K31/395A61K31/664A61K31/737A61K35/12A61K35/28A61K38/193A61K45/06A61K35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,173,175
App. No.
15/239,614
Granted
Nov 16, 2021
Kind
B2
Abstract

The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobilizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients.

Claims (7)

1. A pharmaceutical combination comprising: (a) a uridine diphosphate glucose (UDP-glucose) compound at a dosage of 200 to 500 mg/kg and (b) granulocyte colony stimulating factor (G-CSF) at a dosage of 250 to 300 μg/kg, wherein the combination of the UDP-glucose compound and the G-CSF exhibit synergistic enhancement of hematopoietic stem progenitor cells mobilization.

2. The pharmaceutical combination of claim 1 , further comprising one or more pharmaceutically acceptable carriers.

3. The pharmaceutical combination of claim 1 , further comprising one or more pharmaceutically acceptable excipients.

4. The pharmaceutical combination of claim 1 , wherein the composition is formulated for subcutaneous administration.

5. The pharmaceutical combination of claim 1 , wherein the composition is formulated for intramuscular, intravenous, intraperitoneal, oral, or rectal administration.

6. The pharmaceutical combination of claim 1 , wherein the composition is formulated as a solid formulation.

7. The pharmaceutical combination of claim 1 , wherein the composition is formulated as a liquid formulation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2021
From: LEE, BYEONG-CHEL
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 057260/0740 →
CHANGE OF ADDRESS Recorded Aug 23, 2021
From: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 057265/0213 →
Continuity (4)
Division 14495663 · Sep 24, 2014
Continuation PCTUS2013034452 · Mar 28, 2013
Provisional Application 61618173 · Mar 30, 2012
Related Publication 20160354401A1 · Dec 8, 2016